Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Pancreatic Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors 1Medulloblastoma 1Liver Neoplasms 1Hematologic Neoplasms 1Glioma 1Ependymoma 1Disease 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Cancers 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Temozolomide 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neuroectodermal Tumors × Erlotinib Hydrochloride × Clear all
NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Washington University School of Medicine

Phase 2 Withdrawn
CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡